Amgen isn’t getting much love from Washington these days. The Internal Revenue Service has gone after the biotech for billions of dollars in back taxes. Lina Khan’s Federal Trade Commission is seeking to block its $27.8 billion acquisition of Horizon Therapeutics (a move some insiders think was at …